Protara Therapeutic Inc (TARA) 13F Ownership Report (Q2 2026)

TARA ranks #4171 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

TARA is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

TARA is a top-conviction position for Velan Capital Investment Management LP — at 6.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in TARA belongs to Jupiter Topco LLC, but the position matters far more to Velan Capital Investment Management LP, who has 6.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Qube Research & Technologies Ltd has added to its TARA position for two straight quarters, increasing it by $3.4M to reach $4.0M today.

Integral Health Asset Management, LLC has trimmed its TARA position for two straight quarters, cutting it by $6.3M while still holding $5.7M.

TARA is up 1% today, and institutions have been net buyers of $16.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

TARA reported a net loss of $57.4M in its latest fiscal year.

• Not yet profitable — net loss of $57.4M in the latest fiscal year
• Net income declined year over year, from -$44.6M to -$57.4M
• Operating cash flow was negative, using $56.4M in cash
• Current ratio of 14.58x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.07x equity — within a conventional range